Endo International PLC (NASDAQ:ENDP) Announces Quarterly Earnings Results
Endo International PLC (NASDAQ:ENDP) released its quarterly earnings results on Tuesday. The company reported $0.93 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.19, MarketWatch Earnings reports. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The business had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. During the same period in the previous year, the company earned $0.86 earnings per share. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. Endo International PLC updated its FY17 guidance to $3.35-3.65 EPS.
Endo International PLC (NASDAQ:ENDP) opened at 9.31 on Tuesday. The firm has a 50 day moving average of $11.45 and a 200-day moving average of $11.76. The firm’s market cap is $2.08 billion. Endo International PLC has a 12 month low of $9.21 and a 12 month high of $24.93.
ILLEGAL ACTIVITY WARNING: “Endo International PLC (NASDAQ:ENDP) Announces Quarterly Earnings Results” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/endo-international-plc-nasdaqendp-announces-quarterly-earnings-results.html.
Several equities analysts have issued reports on the stock. Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the stock a “hold” rating in a report on Monday, May 1st. Guggenheim assumed coverage on shares of Endo International PLC in a report on Saturday, June 17th. They issued a “hold” rating and a $12.00 price target on the stock. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a report on Thursday, June 8th. Deutsche Bank AG cut their price target on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, July 7th. Finally, Vetr raised shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $11.34 price target on the stock in a report on Tuesday, May 9th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $17.33.
Several hedge funds have recently added to or reduced their stakes in ENDP. Macquarie Group Ltd. boosted its stake in Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock valued at $107,000 after buying an additional 3,700 shares during the period. James Investment Research Inc. purchased a new stake in Endo International PLC during the second quarter valued at approximately $113,000. Blair William & Co. IL purchased a new stake in Endo International PLC during the second quarter valued at approximately $126,000. Point View Wealth Management Inc. boosted its stake in Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares during the period. Finally, Oakbrook Investments LLC boosted its stake in Endo International PLC by 8.2% in the second quarter. Oakbrook Investments LLC now owns 17,100 shares of the company’s stock valued at $191,000 after buying an additional 1,300 shares during the period. Institutional investors own 93.00% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.